Bragsin1 |
| Katalog-Nr.GC65306 |
Bragsin1 ist ein potenter, selektiver und nicht kompetitiver Inhibitor des ArfGEF. BRAG2 hemmt die Arf-GTPase-Aktivierung mit einem IC50 von 3 μM. Bragsin1 bindet an die PH-DomÄne von BRAG2 und ist ein nicht-kompetitiver GrenzflÄcheninhibitor. Bragsin1 hat keine Wirkung auf die Sec7-DomÄne menschlicher ArfGEFs. Anti-Krebs-AktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 369631-68-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bragsin1 is a potent, selective and noncompetitive inhibitor of the ArfGEF BRAG2, inhibits Arf GTPase activation, with an IC50 of 3 μM. Bragsin1 binds to PH domain of BRAG2, and is a noncompetitive interfacial inhibitor. Bragsin1 has no effect on the Sec7 domain of human ArfGEFs. Anti-cancer activity[1].
[1]. Nawrotek A, et al. PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling. Nat Chem Biol. 2019 Feb 11. doi: 10.1038/s41589-019-0228-3.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *